secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001157523-23-001631
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q3 revenue $47.7M, LIVMARLI sales up 106%; CHENODAL/CHOLBAM acquisition completed
--------------------------------------------------------------------------------

- Q3 2023 total revenue $47.7M (up 154% YoY); LIVMARLI global net sales $38.7M, +106% vs Q3 2022.
- Acquisition of CHENODAL and CHOLBAM closed Aug 31; contributed $9M in Q3 sales.
- Positive Phase 3 RESTORE for CHENODAL in CTX; NDA filing expected H1 2024; sNDA for LIVMARLI in PFIC PDUFA March 13, 2024.
- Cash and investments $306M; convertible debt $316.3M; pipeline catalysts: EMBARK data by year-end, volixibat data H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000115752323001631/0001157523-23-001631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000115752323001631/a53739737.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer